Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Xu, L P  [Clear All Filters]
2024
Fu HX, Li JJ, Zhang YY, Sun YQ, Mo XD, Han TT, Kong J, Lyu M, Han W, Chen H, et al. [Clinical features and risk factors for invasive fungal sinusitis after allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2024;45(1):22-27.
Wang J, Fu HX, Zhang YY, Mo XD, Han TT, Kong J, Sun YQ, Lyu M, Han W, Chen H, et al. [The effect of glucose-6-phosphate dehydrogenase deficiency on allogeneic hematopoietic stem cell transplantation in patients with hematological disorders]. Zhonghua Xue Ye Xue Za Zhi. 2024;45(2):121-127.
Ma N, Wang ZD, Sun YQ, Yan CH, Wang FR, Mo XD, Lyu M, Zhao XY, Zhao XS, Han W, et al. [Effect of sirolimus combined with anti-CD20 monoclonal antibody desensitization on the prognosis of patients underwent haploidentical stem cell transplantation]. Zhonghua Yi Xue Za Zhi. 2024;104(11):843-849.
2023
He Y, Ma R, Wang HF, Zhang YY, Lyu M, Mo XD, Yan CH, Wang Y, Zhang XH, Xu LP, et al. [Clinical analysis of 8 cases of refractory hematopoietic reconstitution after haploid hematopoietic stem cell transplantation treated with purified donor CD34-selected hematopoietic stem cells]. Zhonghua Xue Ye Xue Za Zhi. 2023;44(12):1027-1031.
Sun W, Ma R, He Y, Bai L, Chen YY, Chen Y, Zhang YY, Wang JZ, Chen H, Zhang XH, et al. [Clinical analysis of sirolimus as an alternative GVHD prophylaxis for patients with kidney injury undergoing allo-HSCT]. Zhonghua Nei Ke Za Zhi. 2023;62(12):1444-1450.
Ma R, He Y, Xu LP, Zhang XH, Wang Y, Liu KY, Huang XJ, Sun YQ. [Clinical analysis of the efficacies of ganciclovir plus foscarnet and a single antiviral drug for the treatment of cytomegalovirus infection after haploidentical stem cell transplantation]. Zhonghua Nei Ke Za Zhi. 2023;62(1):76-83.
Ma R, He Y, Wang HF, Bai L, Han W, Cheng YF, Liu KY, Xu LP, Zhang XH, Wang Y, et al. [Clinical analysis of the usefulness of letermovir for prevention of cytomegalovirus infection after haploidentical hematopoietic stem cell transplantation]. Zhonghua Nei Ke Za Zhi. 2023;62(7):826-832.
Han TT, Hong Y, Wei FF, Sun YQ, Yan CH, Mo XD, Wang Y, Zhang XH, Xu LP, Huang XJ, et al. [Clinical characteristics of patients with human adenovirus infection undergoing allogeneic hematopoietic stem cell transplantation]. Zhonghua Nei Ke Za Zhi. 2023;62(2):163-168.
Chen J, Sun YQ, Xu LP, Zhang XH, Liu KY, Mo XD, Cheng YF, Huang XJ, Wang Y. [Dynamic monitoring of plasma Epstein-Barr Virus DNA load can predict the occurrence of lymphoproliferative disorders after haploidentical hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2023;44(4):284-288.
Qin LL, Mo XD, Han TT, Han W, Huang XJ, Xu LP. [Erythrocytosis after hematopoietic stem cell transplantation: report of 3 cases and literature review]. Zhonghua Nei Ke Za Zhi. 2023;62(8):1012-1016.
Lin F, Sun H, Chen Y, Zhang YY, Liu J, He Y, Zheng FM, Xu ZL, Wang FR, Kong J, et al. [Impact of SARS-CoV-2 infection on graft composition and early transplant outcomes following allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2023;44(11):890-899.
Lou R, Xu LP, Zhang XH, Liu KY, Wang Y, Yan CH, Huang XJ, Sun YQ. [Incidence and clinical characteristics of engraftment syndrome after syngeneic hematopoietic stem cell transplantation in patients with hematological diseases]. Zhonghua Xue Ye Xue Za Zhi. 2023;44(4):289-294.
Liu J, Ma R, He Y, Luo XY, Han W, Han TT, Wang Y, Zhang XH, Xu LP, Liu KY, et al. [Prognostic analysis of patients with acute leukemia and central nervous system involvement undergoing allogeneic hematopoietic stem cell transplantation]. Zhonghua Nei Ke Za Zhi. 2023;62(11):1295-1302.
Ma L, Zhao T, Chen YY, Jiang H, Xu LP, Zhang XH, Wang Y, Sun YQ, Mo XD, Huang XJ, et al. [Treatment responses, outcomes, and prognostic factors associated with them in patients with secondary acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2023;44(2):124-131.
2022
Liu XX, Kong J, Pan SA, Liu J, Qin YZ, Chang YJ, Wang Y, Zhang XH, Xu LP, Huang XJ, et al. [Dynamic assessment of WT1 for predicting the relapse of acute myeloid leukemia patients with MLL rearrangements after hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2022;43(9):785-787.
Zhao C, Zhao XS, Wang Y, Yan CH, Xu LP, Zhang XH, Liu KY, Huang XJ, Sun YQ. [Incidence and clinical significance of platelet transfusion refractoriness after allogeneic hematopoietic stem cell transplantation in patients with chronic myelomonocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2022;43(9):738-744.
Cao LQ, Zhou JR, Chen YH, Chen H, Han W, Chen Y, Zhang YY, Yan CH, Cheng YF, Mo XD, et al. [Relationship between treatment and prognosis in patients with late-onset severe pneumonia after allogeneic hematopoietic stem cell transplantation]. Beijing Da Xue Xue Bao Yi Xue Ban. 2022;54(5):1013-1020.
Liu Y, Han TT, Chen Y, Chen H, Fu HX, Zhang YY, Wang FR, Wang JZ, Yan CH, Han W, et al. [Safety of rabbit anti-human thymocyte immunoglobulin in second allogeneic hematopoietic stem cell transplantation for patients with hematological diseases]. Zhonghua Xue Ye Xue Za Zhi. 2022;43(10):853-857.
2021
Li N, Huang XJ, Wang Y, Suo P, Xu LP, Liu KY, Zhang XH, Yan CH, Wang FR, Kong J, et al. [BK virus encephalitis in children with hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2021;42(10):823-827.
Liu J, Fu Q, Wang Y, Wang FR, Han W, Ma YR, Yan CH, Han TT, Wang JZ, Wang ZD, et al. [The effect of donor cytomegalovirus serological status on the outcome of allogeneic stem cell transplantation]. Zhonghua Nei Ke Za Zhi. 2021;60(5):459-465.
2020
Liu WB, Sun YQ, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, Chen YY, Han W, Wang FR, et al. [Risk factors analysis for steroid-resistant acute graft versus host disease after haploidentical hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2020;41(2):106-111.
2019
Li ZR, Zhao T, Liu YR, Wang YZ, Xu LP, Zhang XH, Wang Y, Jiang H, Chen YY, Chen H, et al. [Minimal residual disease in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in high-risk]. Zhonghua Xue Ye Xue Za Zhi. 2019;40(7):554-560.
2018
Zhao XS, Mo XD, Hong Y, Chang YJ, Qin YZ, Liu YR, Chen YY, Zhang XH, Xu LP, Huang XJ. [Clinical implication of minimal residue disease monitoring by WT1 gene detection and flow cytometry in myelodysplastic syndrome with allogeneic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2018;39(12):998-1003.